Skip to main content
. 2019 Jan 31;8:F1000 Faculty Rev-132. [Version 1] doi: 10.12688/f1000research.17039.1

Table 1. Summary of included randomised controlled trials.

Author Year Intervention n Study
duration
(weeks)
Harper et al. 25 2000 Ciclosporin burst versus
continuous therapy		 40 52
Granlund et al. 26 2001 Ciclosporin versus UVAB
phototherapy		 38 8
Pacor et al. 27 2004 Ciclosporin versus tacrolimus 30 8
Bemanian et al. 28 2005 Ciclosporin versus intravenous
immunoglobulin		 14 12
Schmitt et al. 29 2010 Ciclosporin versus prednisolone 38 6
El-Khalawany et al. 30 2013 Ciclosporin versus methotrexate 40 12
Koppelhus et al. 31 2014 Ciclosporin versus extracorporeal
photopheresis		 20 30
Jin et al. 32 2015 Ciclosporin versus ciclosporin +
glucosamine		 38 8
Kim et al. 33 2016 Ciclosporin versus ciclosporin +
topical therapy		 60 24
Goujon et al. 34 2017 Ciclosporin versus methotrexate 97 24
Berth-Jones et al. 35 2002 Azathioprine versus placebo 27 12
Meggitt et al. 36 2006 Azathioprine versus placebo 41 12
Schram et al. 37 2011 Azathioprine versus methotrexate 42 12
Gerbens et al. 14 2018 Azathioprine versus methotrexate 35 260
Oldhoff et al. 38 2005 Mepolizumab versus placebo 43 2
Iyengar et al. 39 2013 Omalizumab versus placebo 8 24
Beck et al. 40 2014 Dupilumab versus placebo 30 4
Beck et al. 40 2014 Dupilumab versus placebo 37 4
Beck et al. 40 2014 Dupilumab versus placebo 109 12
Beck et al. 40 2014 Dupilumab + topical
glucocorticoids versus placebo		 31 4
Thaçi et al. 41 2016 Dupilumab versus placebo 379 16
Simpson et al. 23 2016 Dupilumab versus placebo 671 16
Simpson et al. 23 2016 Dupilumab versus placebo 708 16
Blauvelt et al. 42 2017 Dupilumab versus placebo 740 52
de Bruin-Weller et al. 43 2018 Dupilumab versus placebo 390 16
Khattri et al. 44 2017 Ustekinumab versus placebo 33 33
Saeki et al. 45 2017 Ustekinumab versus placebo 79 12
Ruzicka et al. 46 2017 Nemolizumab versus placebo 264 12
Kabashima et al. 47 2018 Nemolizumab versus placebo 191 64
Wollenberg et al. 48 2018 Tralokinumab versus placebo 204 12
Guttman-Yassky et al. 49 2018 Fezakinumab versus placebo 60 10
Guttman-Yassky et al. 50 2018 Baricitinib versus placebo 124 16
Simpson et al. 51 2018 Lebrikizumab versus placebo 209 12